Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practice (Q38248822)

1 September 2017

1 reference

title

Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practice (English)

1 reference

1 September 2017

1 reference

4

Ruth Knüchel

1 reference

1 September 2017

James W Catto

2

0 references

Lambertus Kiemeney

object named as

Lambertus A Kiemeney

10

0 references

Shahrokh Shariat

5

object named as

Shahrokh F Shariat

1 reference

1 September 2017

1

Bas W G van Rhijn

1 reference

1 September 2017

3

Peter J Goebell

1 reference

1 September 2017

Henk G van der Poel

6

1 reference

1 September 2017

Marta Sanchez-Carbayo

7

1 reference

1 September 2017

George N Thalmann

8

1 reference

1 September 2017

Bernd J Schmitz-Dräger

9

1 reference

1 September 2017

language of work or name

English

0 references

publication date

10 September 2014

1 reference

1 September 2017

1 reference

1 September 2017

volume

32

1 reference

1 September 2017

issue

7

1 reference

1 September 2017

page(s)

1078-1087

1 reference

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

The health economics of bladder cancer: a comprehensive review of the published literature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Long-term follow-up of noninvasive bladder tumours (stage Ta): recurrence and progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Multivariate analysis of the prognostic factors of primary superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Primary superficial bladder cancer risk groups according to progression, mortality and recurrence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

NMIBC risk calculators: how useful are they for the practicing urologist and how can their clinical utility be improved?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Prediction of Progression of Non–Muscle-Invasive Bladder Cancer by WHO 1973 and 2004 Grading and by FGFR3 Mutation Status: A Prospective Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Prognostic value of p53 for high risk superficial bladder cancer with long-term followup.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Mcm2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Identifying distinct classes of bladder carcinoma using microarrays.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Gene Expression Signatures Predict Outcome in Non-Muscle-Invasive Bladder Carcinoma: A Multicenter Validation Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Promoter hypermethylation identifies progression risk in bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Genomics: a preview of genomic medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Molecular Grade (FGFR3/MIB-1) and EORTC Risk Scores Are Predictive in Primary Non–Muscle-Invasive Bladder Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

p53 immunohistochemistry in bladder cancer--a new approach to an old question

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

P53 as a prognostic marker for bladder cancer: a meta-analysis and review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Prediction of stage, grade, and survival in bladder cancer using genome-wide expression data: a validation study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Toward a molecular pathologic classification of urothelial carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Pathological stage review is indicated in primary pT1 bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Statistical consideration for clinical biomarker research in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Guidelines for development of diagnostic markers in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Reporting recommendations for tumor marker prognostic studies (REMARK).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

Perioperative chemotherapy in muscle-invasive bladder cancer: overview and the unmet clinical need for alternative adjuvant therapy as studied in the MAGNOLIA trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.07.002

10.1016/J.UROLONC.2014.07.002

7 January 2021

Identifiers

DOI

1 reference

1 September 2017

1 reference